Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budigalimab and/or ABBV-382 during analytical treatment interruption in adults with HIV on stable ART
2023-505900-53-00Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of budigalimab and ABBV-382 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Viral control at Week 24 without ART restart. Started Apr 2024; status: completed.
02
Drugs
budigalimabABBV-382
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2023-505900-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505900-53-00.